Developer docs
API playgroundTry for free, no card

Search company profiles

AXIM Biotechnologies

Full company profile

uuid000gejv

Namestring
AXIM Biotechnologies
Websiteurl
aximbiotech.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

AXIM Biotechnologies is identified by its corporate name and the domain aximbiotech.com, which together indicate a positioning within the biotechnology sector. The company name itself signals a focus on biotechnological research, development, or commercialization, though no specific therapeutic area, modality, or product pipeline is described in the available source material. All other operational dimensions — products and services, proprietary technology, pricing model, go-to-market motion, customer segments, distribution channels, geographic footprint, partnerships, intellectual property, leadership, and operating status — are absent from the supplied data, and the company's own website was inaccessible due to a CAPTCHA/verification page, preventing any first-party validation.

No revenue figures, funding history, headcount, or financial disclosures are available in the source data. The provided metadata explicitly states that legal name, founding date, company type, operating status, revenue, and domicile could not be determined from available source data because the website was blocked. No management team, board, regulatory actions, mergers and acquisitions, restructuring events, or product launches are recorded in the supplied dataset. As a result, any further characterization of the company's business model, competitive positioning, or operational scale cannot be grounded in the input and is deliberately omitted from this description.

Short descriptiontext

AXIM Biotechnologies is a biotechnology-sector company identified by its name and domain aximbiotech.com; specific products, technology, customer segments, and operational status are not disclosed in the available source data.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword1 value
biotechnology products
Industry2 codes
1Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
CodeHLAAAIAIPrimaryYes
2Analytical Development & QC Testing (Release/Stability/Potency)
CodeHLAGAGAFPrimaryNo
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biotechnology
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

The source data contains no information about what AXIM Biotechnologies fundamentally does or sells; the company's website was blocked by a CAPTCHA/verification page and no product or service descriptions were retrieved.

Differentiator
Functional benefit
Problem solved
No data
Peers5 records
TypeDirect peer
Description

Developed cannabinoid-based prescription therapeutics (e.g., Sativex, Epidiolex) for neurological and rare disease indications. Historically the most direct comparator to AXIM's cannabinoid therapeutics platform.

TypeDirect peer
Description

Clinical-stage cannabinoid therapeutics company focused on transdermal cannabinoid formulations for neurological and inflammatory conditions, with overlapping therapeutic-area focus to AXIM's clinical programs.

TypeDirect peer
Description

Pharmaceutical company developing cannabinoid-based prescription therapeutics using both rare cannabinoid compounds and proprietary manufacturing approaches; comparable biotech/cannabinoid model.

TypeDirect peer
Description

Cannabinoid-derived prescription drug development company focused on oncology, ophthalmology, and pain — directly comparable therapeutic focus and small-cap biotech profile.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company that historically pursued cannabinoid receptor-targeting therapeutics for inflammatory and fibrotic diseases, providing a relevant peer comparable.

Market position
Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat1 record

Each record includes

Type, Details

Key risks1 record

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

No data
Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AXIM Biotechnologies

Biotechnologyaximbiotech.com

AXIM Biotechnologies is a biotechnology-sector company identified by its name and domain aximbiotech.com; specific products, technology, customer segments, and operational status are not disclosed in the available source data.

What AXIM Biotechnologies does

AXIM Biotechnologies is identified by its corporate name and the domain aximbiotech.com, which together indicate a positioning within the biotechnology sector. The company name itself signals a focus on biotechnological research, development, or commercialization, though no specific therapeutic area, modality, or product pipeline is described in the available source material. All other operational dimensions — products and services, proprietary technology, pricing model, go-to-market motion, customer segments, distribution channels, geographic footprint, partnerships, intellectual property, leadership, and operating status — are absent from the supplied data, and the company's own website was inaccessible due to a CAPTCHA/verification page, preventing any first-party validation.

No revenue figures, funding history, headcount, or financial disclosures are available in the source data. The provided metadata explicitly states that legal name, founding date, company type, operating status, revenue, and domicile could not be determined from available source data because the website was blocked. No management team, board, regulatory actions, mergers and acquisitions, restructuring events, or product launches are recorded in the supplied dataset. As a result, any further characterization of the company's business model, competitive positioning, or operational scale cannot be grounded in the input and is deliberately omitted from this description.

AXIM Biotechnologies firmographics

Firmographics
Name
AXIM Biotechnologies
Website
https://aximbiotech.com
Company type
Private
Founded year
2010
Headcount range
11–50 employees
Short description
AXIM Biotechnologies is a biotechnology-sector company identified by its name and domain aximbiotech.com; specific products, technology, customer segments, and operational status are not disclosed in the available source data.
Ownership category
akta.pro rank

AXIM Biotechnologies industry classification

Industry
Product category
Biotechnology
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro primary industry
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
akta.pro secondary industry
Analytical Development & QC Testing (Release/Stability/Potency) (HLAGAGAF)

Keywords

  • Biotechnology products

Where AXIM Biotechnologies is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Markets served

AXIM Biotechnologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing

AXIM Biotechnologies product offering

Product offering

Core offering

The source data contains no information about what AXIM Biotechnologies fundamentally does or sells; the company's website was blocked by a CAPTCHA/verification page and no product or service descriptions were retrieved.

Differentiator

Problem solved

Functional benefit

AXIM Biotechnologies technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AXIM Biotechnologies competitors and assessment

Company assessment

Direct peers

  • GW Pharmaceuticals: Developed cannabinoid-based prescription therapeutics (e.g., Sativex, Epidiolex) for neurological and rare disease indications. Historically the most direct comparator to AXIM's cannabinoid therapeutics platform.
  • Zynerba Pharmaceuticals: Clinical-stage cannabinoid therapeutics company focused on transdermal cannabinoid formulations for neurological and inflammatory conditions, with overlapping therapeutic-area focus to AXIM's clinical programs.
  • InMed Pharmaceuticals: Pharmaceutical company developing cannabinoid-based prescription therapeutics using both rare cannabinoid compounds and proprietary manufacturing approaches; comparable biotech/cannabinoid model.
  • Tetra Bio-Pharma: Cannabinoid-derived prescription drug development company focused on oncology, ophthalmology, and pain — directly comparable therapeutic focus and small-cap biotech profile.
  • Corbus Pharmaceuticals: Clinical-stage biopharmaceutical company that historically pursued cannabinoid receptor-targeting therapeutics for inflammatory and fibrotic diseases, providing a relevant peer comparable.

Market position

Weaknesses1 record

Competitive moat1 record

Key risks1 record

Customer concentration

AXIM Biotechnologies social profiles

Digital presence

AXIM Biotechnologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AXIM Biotechnologies leadership team

Management profile

Number of profiles

AXIM Biotechnologies funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AXIM Biotechnologies M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AXIM Biotechnologies

What does AXIM Biotechnologies do?

The source data contains no information about what AXIM Biotechnologies fundamentally does or sells; the company's website was blocked by a CAPTCHA/verification page and no product or service descriptions were retrieved.

When was AXIM Biotechnologies founded?

AXIM Biotechnologies was founded in 2010. It employs 11 to 50 people.

Where is AXIM Biotechnologies based?

AXIM Biotechnologies is headquartered in New York, United States, in the North America region.

Who are AXIM Biotechnologies's main competitors?

Direct peers on record are GW Pharmaceuticals, Zynerba Pharmaceuticals, InMed Pharmaceuticals, Tetra Bio-Pharma and Corbus Pharmaceuticals.

Does AXIM Biotechnologies have an API?

No public API is recorded for AXIM Biotechnologies.

What industry is AXIM Biotechnologies in?

AXIM Biotechnologies's product category is Biotechnology. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAGAGAF, Analytical Development & QC Testing (Release/Stability/Potency). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsAXIM Biotechnologies, Inc. (OTCMKTS:AXIM) Shares Shorted: Short Interest Up 373.7% in SeptemberShort interest in AXIM Biotechnologies rose 373.7% to 90,412 shares as of September 15th, up from 19,085 on August 31st. The stock opened at $0.00, down 2.7%, with a 12-month range of $0.00 to $0.03. The company focuses on diagnostic platforms for ophthalmic conditions.GlobeNewswireAXIM Biotechnologies Commercial Partner Verséa Ophthalmics Highlights Benefits of AXIM’s Eye Diagnostic SolutionsAXIM Biotechnologies announced its ophthalmic tear-based diagnostic tests were featured in Eyes On 2023 and Ophthalmology Times, with interviews from Verséa's Dr. Rob Sambursky. The tests include an IgE assay for allergic conjunctivitis and a Lactoferrin test for dry eye, with a new MMP-9 assay planned for Q2 2023.GlobeNewswireAXIM® Biotechnologies Receives Initial Order for Diagnostic Solutions as Exclusive Partner Verséa Ophthalmics Commences Initial Commercial LaunchAXIM Biotechnologies received an initial order of 19,000 point-of-care diagnostic tests and 100 readers for ocular surface diseases from its partner Verséa Ophthalmics. The order, the company's first large-scale revenue-generating event, includes FDA-cleared tear-based tests for dry eye and allergic conjunctivitis. AXIM expects repeat orders from clinicians.GlobeNewswireAXIM Biotechnologies Publishes Study Highlighting Neutralizing Antibody Levels of Poor Vaccine Responders with a Third COVID-19 Vaccine DoseAXIM Biotechnologies and Arizona State University published a study in Communications Medicine showing that a third COVID-19 vaccine dose boosts neutralizing antibodies in poor responders. The study found that 25% of two-dose recipients had inadequate antibodies, and the third dose raised them to protective levels within two weeks.GlobeNewswireAXIM Launches New Eye Care Website; Establishes Platform for CommercializationAXIM Biotechnologies launched a new mobile-optimized website on June 2, 2022, to provide medical professionals with information and resources for purchasing its diagnostic tests. The site features details on FDA 501(k) cleared tests for Dry Eye Disease and ocular allergies, a research library, CLIA application guidelines, and an order form. The company expects the site to increase awareness and streamline sales.GlobeNewswireAXIM Biotechnologies Applauds FDA's Recent COVID-19 Test Policies to Support Rapid Neutralizing Antibody TestsAXIM Biotechnologies applauded the FDA's updated COVID-19 test policies, which prioritize emergency use authorization for high-volume neutralizing antibody tests. The company has developed three such tests, with a point-of-care qualitative test pending EUA in Canada and the EU. The tests demonstrated over 90% sensitivity and 100% specificity in benchmarking.GlobeNewswireAXIM Biotechnologies’ Development of Rapid Test for COVID-19 Neutralizing Antibodies is Cited to Demonstrate over 90% Sensitivity and 100% SpecificityAXIM Biotechnologies published a rapid test for SARS-CoV-2 neutralizing antibodies, the first to semi-quantitatively measure functional antibodies. The test showed over 90% sensitivity and 100% specificity against an authentic assay, and does not cross-react with seasonal respiratory viruses. CEO John Huemoeller said it may help identify declining protective antibodies, suggesting booster shots.GlobeNewswireAXIM® Biotechnologies Appoints Senior DED Expert Dr. Laura Periman to its Medical Advisory BoardAXIM Biotechnologies appointed Dr. Laura Periman, MD, to its Medical Advisory Board, joining Chairman Dr. Joseph Tauber. She brings 30 years of experience in ocular surface disease and dry eye disease, including founding the Periman Eye Institute. The board will guide strategy for commercializing ophthalmic diagnostic lab tests.GlobeNewswireMedical Marijuana, Inc. Investment Company AXIM® Biotechnologies Files Patent for World’s First Face Mask Designed to Capture SARS-CoV-2 (COVID-19)AXIM Biotechnologies, an investment company of Medical Marijuana, Inc., filed a provisional patent for a face mask that captures and deactivates SARS-CoV-2. The mask uses proprietary reagents embedded in the filter to bind the virus, and AXIM is examining FDA or EPA approval pathways. The company plans to license manufacturers for large-scale production.GlobeNewswireSapphire Biotech, Subsidiary of AXIM® Biotechnologies, Awarded Prestigious Phase I Small Business Innovation Research Grant by National Cancer InstituteSapphire Biotech, a subsidiary of AXIM Biotechnologies, received a $395,880 Phase I SBIR grant from the National Cancer Institute to develop small-molecule inhibitors of QSOX1, a tumor-derived enzyme linked to metastasis. The grant will support analog synthesis and preclinical studies, with results guiding new compound development.